H.C. Wainwright raised the firm’s price target on X4 Pharmaceuticals (XFOR) to $5 from $3.50 and keeps a Buy rating on the shares post the Q3 report. The company executed a corporate restructuring to ensure long-term growth, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XFOR:
- X4 Pharmaceuticals Focuses on Chronic Neutropenia Trial
- X4 Pharmaceuticals price target lowered to $7.50 from $9 at Stifel
- X4 Pharmaceuticals reports Q3 EPS (69c), consensus (84c)
- X4 Pharmaceuticals 45.87M share Spot Secondary priced at $2.85
- X4 Pharmaceuticals announces common stock offering, no amount given